| Literature DB >> 36034701 |
Xiaoying Zhou1,2, Shengchun Jin2, Jingyi Pan2, Qingyi Lin2, Shaopeng Yang2, Peter C Ambe3, Zarrin Basharat4, Vincent Zimmer5,6, Wei Wang7,8, Wandong Hong1.
Abstract
Previous researches have emphasized a trypsin-centered theory of acute pancreatitis (AP) for more than a century. With additional studies into the pathogenesis of AP, new mechanisms have been explored. Among them, the role of immune response bears great importance. Pro-inflammatory substances, especially damage-associated molecular patterns (DAMPs), play an essential role in activating, signaling, and steering inflammation. Meanwhile, activated neutrophils attach great importance to the immune defense by forming neutrophil extracellular traps (NETs), which cause ductal obstruction, premature trypsinogen activation, and modulate inflammation. In this review, we discuss the latest advances in understanding the pathological role of DAMPs and NETs in AP and shed light on the flexible crosstalk between these vital inflammatory mediators. We, then highlight the potentially promising treatment for AP targeting DAMPs and NETs, with a focus on novel insights into the mechanism, diagnosis, and management of AP.Entities:
Keywords: DAMPs (damage-associated molecular patterns); HMGB1 (high mobility group box 1); HSP (heat shock protein); NETs (neutrophil extracellular traps); acute pancreatitis (AP); histone
Mesh:
Substances:
Year: 2022 PMID: 36034701 PMCID: PMC9411527 DOI: 10.3389/fcimb.2022.927193
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
DAMPs receptors, associated DAMPs, expression pattern and their effects related to AP.
| DAMP receptors | DAMPs | Expression pattern | Main effect | Refs |
|---|---|---|---|---|
| TLR | Ubiquitous, high in immune cells | Promote the expression of pro-inflammatory genes, thus upregulate the production of cytokines, chemokines, and adhesion molecules. | ( | |
| TLR2 | HMGB1, HSP60, HSP70, histone | |||
| TLR4 | HMGB1, HSP22, HSP60, HSP70, HSP72, histone | |||
| TLR9 | DNA, HMGB1 | |||
| NLRP3 | ATP | DCs, neutrophils, monocytes and macrophages | Promote the activation of caspase-1. Increase the secretion of IL-1β and IL-18. Initiate pyroptosis. | ( |
| RAGE | HMGB1 | Ubiquitous, high in T cells, B cells, and macrophages | Promote the expression of pro-inflammatory genes. Mediate cell migrationand apoptosis. | ( |
| P2X7R | ATP | Ubiquitous | Promote the release of cytokine and chemokine, the activation of NLRP3 inflammasome, transcription factor and T cells. | ( |
| P2Y2R | ATP | Ubiquitous, high in immune cells, epithelial and endothelial cells | Promote the migration, and activation of immune cells. Control iron channels. | ( |
Figure 1HMGB1 could be released by acinar cells and other cells in both active and passive ways. It participates in the formation of NETs and induce other acinar cell necrosis to boost the inflammation, therefore enhance the pathological process of AP. Meanwhile, HMGB1 is involved in lung and intestinal injury secondary to AP and serves as a pain mediator.
Figure 2DNA mediated inflammation via DAMPs receptors and STING signaling. Double-stranded DNA and DNA fragments were released from dying acinar cells. DsDNA activated the NF-KB and MAPK pathway through toll-like receptors to induce AP-associated inflammation. DNA fragments worsen AP-associated inflammation through STING signaling pathway in macrophages.
Figure 3Proposed immunopathological roles of circulating histones in acute pancreatitis. DAMPs activate innate immune cells (neutrophils and macrophages) and endothelial cells through PRRs, triggering highly inflammatory programmed cell death such as neutrophil extracellular traps, necroptosis and necrosis. Extracellular histones mediate inflammation response, organ injury and death through TLR and NLRP3 inflammasome pathways.
Figure 4Extracellular CIRP (eCIRP) is released to the extracellular space via necrosis or lysozyme extracellular pathway, afterward binds to the TLR4-MD2 receptor complex on macrophages, activates the TLR4/MyD88/NF-κB pathway and induces macrophages to release pro-inflammatory cytokines (TNF-A, IL-6, Il-1b), chemokines (keratinocyte chemical attractor and MIP-2), and HMGB1. This pathway also promotes mitochondrial DNA damage and degradation, leading to STING activation, which leads to the production of type I IFN and pro-inflammatory cytokines.
Figure 5The intracellular DAMPs is released to the outside of the cell and can recognize PRR on surrounding neutrophils, and in turn, activate PAD4 to promote NET formation. NETs components, such as DNA and H3 histones, can further activate macrophages and endothelial cells, releasing more DAMPs out of the cell to amplify the inflammatory cascade.
Intervention of DAMPs in AP therapy, with intervention type, targeted DAMPs and associated mechanism.
| Intervention type | Substance | Targeted DAMPs | Mechanism | Reference |
|---|---|---|---|---|
| Decrease expression of extracellular | LincRNA-EPS; Dexamethasone; Midazolam combined with sufentanil; pRNA-U6.1/Neo; Calycosin; Sodium Butyrate;microRNA-141; miR-340-5p; Danaparoid sodium | HMGB1 | Suppress the HMGB1-NF-κB-dependent inflammation gene expression | ( |
| Increase the expression of intracellular DAMPs | Hydrogen-rich gases | HSP | Increase the expression of HSP60 and resist the oxidation | ( |
| BRX-220 | HSP | Increase the production of HSPs incluing HSP60 and HSP72 | ( | |
| Bortezomib | Induce the pancreatic HSP72 and inhibit the proteosome | ( | ||
| Insulin and insulin-mimetics | ATP | Upregulate glycolysis, prevent POA-induced ATP depletion, and inhibit Ca2+ overload | ( | |
| Cyclosporin A derivative (NIM811) | Serve as a cyclophilin D inhibitor to inhibit the opening of the mitochondrial | ( | ||
| Enhancing DAMPs elimination | HMGB1 neutralizing antibody | HMGB1 | Bock high-mobility group box 1 and reduce the TLR4 and TLR9 expression | ( |
| Heparin, Activated protein C, Thrombomodulin | Histones | Bind and inactivate histones | ( | |
| IRS954 | Block TLR to reduce pancreatic edema and inflammatory | ( | ||
| Blocking DAMPs signaling | Protocatechuic acid; ALR;Abdominal paracentesis drainage; | HMGB1 | Target HMGB1/TLR4/NF-κB signaling pathway | ( |
| Suramin | eATP | Block the P2 receptors and lead to reduced levels of plasma IL-6 and TNF-α | ( |
Intervention in NETs, and their mechanisms in AP therapy.
| Substance | Mechanism | Reference |
|---|---|---|
| Chloroquine | Reduce serum cell-free DNA and citrullinated histone H3 in murine models of pancreatitis to regulate NET formation | ( |
| C3 gene-deficient | Disrupt complement cascades, reduce chemokine secretion, as well as decrease early infiltration of neutrophils into the pancreas and neutrophil extracellular traps formation through PAD4. | ( |
| GZD824 | Abolish activation of c-Abl kinase to regulate NET formation, as well as decrease levels of citrullinated histone 3 in the pancreas and DNA-histone complexes in the plasma. | ( |
| Cl‐amidine and GSK484 | Reduce taurocholate‐induced increase of histone 3 citrullination in the pancreas and DNA‐histone complexes in the plasma to regulate NET formation | ( |
| Platelet IP6K1 gene-deficient | Induce exogenous PolyP to regulate NET formation | ( |
| PD1 | Decrease early infiltration of neutrophils into the pancreas and neutrophil extracellular traps formation through PAD4. | ( |
| DAMPs | Damage associated molecular patterns |
| NETs | neutrophil extracellular traps |
| AP | Acute Pancreatitis |
| ER | endoscoplasmatic retiuculum |
| NF- κb | nuclear factor-κb |
| RyR | ryanodine receptor |
| MPTP | mitochondrial permeability transition pore |
| SIRS | systemic inflammation reaction syndrome |
| LPS | bacterial lipopolysaccharide |
| PMA | phorbol 12-myristate 13-acetate |
| PKC | protein kinase C |
| PRR | pattern recognition receptors |
| NLR | nod like receptor |
| RIG-I | retinoic acid-inducible gene I |
| RAGE | receptors for advanced glycation end |
| HMGB1 | high mobility group box-1 |
| TLR | toll-like receptors |
| MALAT1 | metastasis associated lung adenocarcinoma transcript-1 |
| HSPs | heat shock proteins |
| HSF-1 | heat shock factor protein 1 |
| CD | cluster of differentiation |
| STING | (stimulator of the interferon gene) |
| MAPKs | mitogen-activated protein kinases |
| MYD88 | major reactive protein 88 |
| cGAS | cyclic GMP–AMP |
| BMDCs | bone marrow-derived dendritic cells |
| SERCAs | channels in the smooth ER |
| UPR | unfolded protein response |
| AKs | adenylate kinases |
| NDPK/NME | nucleoside diphosphate kinase |
| NFAT | nuclear factor of activated T cells |
| HIF1α | hypoxia-inducible factor 1α |
| CIRP | cold-inducible RNA-binding protein |
| NE | neutrophil elastase |
| MPO | myeloperoxidase |
| PR3 | leukocyte proteinase 3 |
| NOX | NADPH oxidase |
| PAD4 | peptidyl arginine deaminase 4 |
| ROS | reactive oxygene species |
| MAC-1 | macrophage-1 antigen |
| MMP-9 | matrix metallopeptidase-9 |
| cfDNA | cell free DNA |
| DIC | disseminated intravascular coagation |
| Rac2 | Ras-related C3 botulinum toxin substrate 2 |
| CitH3 | citrullinated histone 3 |
| PMNs | polymorphonuclear leukocytes |
| BM-PMNs | bone marrow-derived PMN |